Here are the 3 most-used drugs on the Medicare price negotiation list
Publishing timestamp: 2023-08-29 19:22:41
Summary
The Biden administration has unveiled a list of 10 drugs that will be subject to price negotiations between manufacturers and Medicare. The list includes two blood thinners and a diabetes medication that are widely used by Medicare enrollees. The goal of the process is to control rising drug costs for older adults in the U.S. The most widely used drug among Medicare enrollees is Bristol-Myers Squibb's blood thinner Eliquis, followed by Boehringer Ingelheim's Jardiance and Johnson & Johnson's blood thinner Xarelto. The negotiations will conclude in August 2024, and the reduced prices will go into effect in January 2026.
Sentiment: NEUTRAL
Keywords: centers for medicare & medicaid services, breaking news: politics, health care industry, business, pharmaceuticals, business news, politics, biotech and pharmaceuticals, pfizer inc, johnson & johnson, bristol-myers squibb co, social issues, biotechnology, breaking news,